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ABSTRACT
This report is an analysis of the structure of the compound biological effectiveness (CBE) factor. The value of the
CBE factor previously reported was revalued for the central nervous system, skin and lung. To describe the struc-
ture, the following terms are introduced: the vascular CBE (v-CBE), intraluminal CBE (il-CBE), extraluminal CBE
(el-CBE) and non-vascular CBE (nv-CBE) factors and the geometric biological factor (GBF), i.e. the contribu-
tions that are derived from the total dose to the vasculature, each dose to vasculature from the intraluminal side
and the extraluminal side, the dose to the non-vascular tissue and the factor to calculate el-CBE from il-CBE,
respectively. The el-CBE factor element was also introduced to relate il-CBE to el-CBE factors. A CBE factor of
0.36 for disodium mercaptoundecahydrododecaborate (BSH) for the CNS was independent of the 10B level in the
blood; however, that for p-Boron-L-phenylalanine (BPA) increased with the 10B level ratio of the normal tissue to
the blood (N/B). The CBE factor was expressed as follows: factor = 0.32 + N/B × 1.65. The factor of 0.32 at 0 of
N/B was close to the CBE factor for BSH. GBFs had similar values, between BSH and BPA, 1.39 and 1.52, respect-
ively. The structure of the CBE factor for BPA to the lung was also elucidated based on this idea. The factor is
described as follows: CBE factor = 0.32 + N/B × 1.80. By this elucidation of the structure of the CBE factor, it is
expected that basic and clinical research into boron neutron capture therapy will progress.
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INTRODUCTION
Boron neutron capture therapy (BNCT) is one of high linear-energy-
transfer (LET) particle radiotherapies. The 10B nucleus efﬁciently cap-
tures thermal neutrons with energy of <0.5 eV and emits two particles
following the reaction: 10B(n,α)7Li. The cross-section of this reaction is
∼2000 times larger than that of the nitrogen–neutron reaction, 14N(n,
p)14C, which has the largest cross-section among the elements compos-
ing human tissue. Moreover, track ranges of these particles are extremely
short, ∼9 μm and 4 μm, respectively, for the α particle and the 7Li
nucleus. Because they deposit all their kinetic energy in short ranges, the
particles are high-LET radiations. Their track ranges are also shorter than
the diameters of general cells. Therefore, if a 10B atom accumulates select-
ively in a tumor cell, it would be destroyed by the irradiation of neutrons.
BNCT has been tried for treating X-ray refractory cancers for
various reasons. Since no effective alternative treatments exist, recurrent
cases of glioblastoma have been regarded as good target cancers from
the ﬁrst stage of clinical development [1, 2]. BNCT for malignant
melanoma has also been tried, based upon the X-ray–resistant nature
of the melanoma cell [3].
BNCT is an attractive treatment; however, it is difﬁcult for general
radiation oncologists to understand and the research into BNCT is
still limited to small groups. The major reason is the difﬁculty of dose
assessment to the tumors and also to normal tissues. This is because
the area in which the α particle and 7Li nucleus deliver their doses is
roughly localized to the 10B-accumulated cells. In general, the micro-
distribution of 10B compounds in a tumor is not uniform because
they are distributing through tumor vasculature, and accumulation
depends on the biological natures or states of tumor cells [4–6]. This
heterogeneous distribution occurs also in normal tissue because the
normal tissue consists of various kinds of cells and structures with
different characters with respect to the status of proliferation and/or
transportation of chemicals [7–11].
In radiotherapy, the maximum dose given to a lesion is generally
limited by the late damage to the surrounding normal tissue. In
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high-LET radiotherapy, the dose concept of Gy-Eq, in which relative
biological effectiveness (RBE) is simply multiplied by the absorbed
physical dose, is generally used. RBE is determined by comparing the
doses of X-rays and high-LET radiation concerned to give an equal
biological effect. In BNCT, because of the heterogeneous microdistri-
bution of 10B compound in the tissue, the radiation dose is heteroge-
neously delivered to the cells as described above. In addition to this,
the cell populations involved in the radiation effect, especially in late
damage, are indeﬁnite. Therefore, it is impossible to determine the
RBE of BNCT as easily and accurately as is usual for high-LET radi-
ation beams for external radiotherapy.
To solve this problem, a very clever and smart concept was pro-
posed by Morris et al. in 1994 [12]—the compound biological effect-
iveness (CBE) factor. The calculation formula is as follows and looks
very similar to that of the usual RBE. Effective dose 50 (ED50) is the
dose to induce a prescribed level of radiation injury in 50% of the test
animals.
CBE factor ¼ ðX-ray ED50 - Neutron Beam ED50
× RBEÞ=10Bðn; αÞ7Li Dose ð1Þ
The main difference between the RBE and the CBE factor calculation
is in the absorbed radiation dose. In the determination of the RBE,
the actual radiation dose to the tissue is applied. However, in the
determination of the CBE factor, the radiation dose is calculated by
assuming that the 10B compound is distributed uniformly throughout
the tissue at a level equal to that in the blood. The CBE factor calcula-
tion is based on this assumed dose. This CBE concept is very con-
venient for the clinical practice of BNCT. The 10B level in the blood
and the neutron ﬂuence to the tissue can be easily measured or esti-
mated during neutron irradiation. Thus, the radiation oncologist can
calculate the biologically X-ray–equivalent tissue dose by multiplying
the CBE factor by the assumed physical dose and taking into consid-
eration the tolerance of normal tissue to BNCT. However, the RBE
and the CBE factor can change markedly with compound, tissue or
the combination of both [12–17]. For these reasons, the factors
are determined by animal experiments for each combination of
compound and tissue. This requires a lot of labor, time and research
expense. In order to reduce the laborious work of determining CBE
factors, and consequently to advance clinical BNCT, the reported
data were reanalyzed to reveal the structure of the CBE factor.
MATERIALS AND METHODS
The adjustment of the CBE factor for disodium
mercaptoundecahydrododecaborate for the central
nervous system by the corrected RBE of the neutron
beam itself
The RBE of the neutron beam itself is determined through the com-
parison of the ED50s of the X-ray and the neutron beams at an initial
step. Thereafter, an experiment using the neutron beam combined
with the 10B compound is performed to obtain a dose–effect curve. By
analyzing the dose–effect curve, the CBE factor for the 10B compound
is calculated. Morris et al. reported CBE factors for disodium mercap-
toundecahydrododecaborate (BSH: Na2B12H11SH) and p-Boron-
L-phenylalanine (BPA: C9H12BNO4) determined using radiation
myelopathy as an endpoint [15, 17]. In 1997, his group reported the
important observation that the RBE of the Brookhaven Medical
Research Reactor (BMRR) neutron beam varied with neutron dose
itself. Therefore, the CBE factors determined using a ﬁxed RBE were
not accurate [18]. They reassessed the CBE factors for BPA taking into
account the variation in the RBE of the neutron beam according to
dose (Table 1). However, the CBE factors were not reassessed for
BSH (Table 2). In this study, the RBE was reassessed using the RBE
versus neutron dose relation curve that was applied to adjust the CBE
factors for BPA (Fig. 1). Subsequently, the CBE factors for BSH previ-
ously reported in 1996 by Morris et al. were adjusted.
Analysis of the relationship between the CBE factor for
BPA to the central nervous system and N (normal
tissue)/B (blood) of the 10B level
Morris et al. noted that the CBE factor, using radiation myelitis as an
endpoint, varied with the BPA dose administered. Furthermore, it was
also recognized that the BPA dose inﬂuenced the N/B of the 10B level
Table 1. ED50, Neutron component, 10B(n,α)7Li component, RBE and CBE factors for radiation myelopathy following X-ray



























93 25.0 ± 0.6 3.4 ± 0.7 21.6 ± 0.5 0.66 ± 0.07 2.57 0.48 0.1
42 17.5 ± 0.7 4.6 ± 0.9 12.9 ± 0.6 0.97 ± 0.11 2.25 0.67 0.2
19 13.8 ± 0.6 7.0 ± 0.5 6.8 ± 0.2 1.34 ± 0.13 1.86 0.88 0.33
12 13.8 ± 0.5 8.9 ± 0.4 4.9 ± 0.7 1.33 ± 0.16 1.67 0.85 0.33
0 13.6 ± 0.4 13.6 ± 0.4 0 19.0 ± 0.2/13.6 ± 0.4
= 1.40 ± 0.04
19.0 ± 0.2/13.6 ± 0.4
= 1.40 ± 0.04
X-rays 19.0 ± 0.2 0 0
aThe author has selected the values for N/B of the 10B level from the paper by GM Morris (1997) [18]. The values written in italics are the data reported in the original
tables in reference [18].
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[18]. Their data reported are in Table 1. However, Morris et al. did not
analyze the data further. In the present study, their data on the CBE
factor for BPA have been reanalyzed, especially with respect to the quan-
titative relation between the CBE factor and the N/B for the 10B level.
Analysis of the structure of the CBE factor for BSH and
BPA to the central nervous system
A healthy blood–brain barrier inhibits penetration of BSH into the
central nervous system (CNS) [7, 8]. Consequently, the CBE factor
for BSH to the spinal cord is considered to be derived from the radi-
ation dose irradiated to the vasculature from the intraluminal side.
BPA, however, can penetrate the blood–brain barrier and enter the
CNS, and the vasculature receives radiation from both sides; the non-
vascular tissue also receives radiation. Taking into account these dif-
ferences in radiation dose deposition, the CBE factors for BSH and
BPA were compared and the structure of the CBE factor was eluci-
dated quantitatively.
The structure of the CBE factor and its components
were applied to the understanding of late damage
to the skin and lung
The precedent radiation pathology study [19] revealed that radiation
injury of the vasculature is the cause of late reaction of the skin (der-
mal necrosis). In the lung, it is thought that radiation pneumonitis is
induced via two pathways [20]: damage to an alveolar type II cell ini-
tiating the ﬁrst process, and damage to an endothelial cell prompting
the second. These pathways interact with each other to stimulate the
differentiation of progenitor ﬁbroblast cells into ﬁbroblasts, which
eventually generates collagen, through the aid of macrophages and
cytokines. So, whether the late effect (caused by different mechan-
isms) to these two organs could be explained by the structure of the
CBE factor was investigated.
RESULTS
Adjustment of CBE factors for BSH to the CNS by the
corrected RBE of the neutron beam itself
Using the relation between the neutron beam dose and the RBE in
Fig. 1, the RBE for each neutron dose reported in the literature by
Morris et al. was reevaluated. In their paper, a ﬁxed value for the RBE
of 1.40 was applied in calculating the CBE factor for BSH; however,
the RBE increased from 1.62 to 2.50 with decrease in the neutron
dose from 13.6 Gy to 3.6 Gy after reevaluation. By using these
corrected neutron RBEs, the CBE factor for BSH was recalculated
using Formula 1. The original CBE factor before recalculation ranged
around 0.52, but it ranged around 0.36 after recalculation (Table 2).
The relationship between the CBE factor and the 10B level in the
blood is presented in Fig. 2, both before and after recalculation. The
factors were stable and independent of the 10B level in the blood.
Table 2. ED50, Neutron component, 10B(n,α)7Li component, RBE and CBE factors for myelopathy following X-ray and neutron












Original RBE or original









190 32.4 ± 1.9 3.6 ± 0.2 28.8 ± 1.92 0.49 ± 0.03 2.50 0.35
140 28.4 ± 0.6 4.1 ± 0.1 24.3 ± 0.6 0.55 ± 0.02 2.36 0.38
80 27.2 ± 0.9 5.2 ± 0.2 22.0 ± 0.9 0.53 ± 0.03 2.13 0.36
40 24.9 ± 1.2 7.3 ± 0.2 17.6 ± 1.2 0.50 ± 0.04 1.80 0.33
20 20.7 ± 1.9 9.2 ± 0.2 11.5 ± 1.9 0.53 ± 0.10 1.62 0.36
0 13.6 ± 0.4 13.6 ± 0.4 0 19.0 ± 0.2/13.6 ± 0.4
= 1.40 ± 0.04
19.0 ± 0.2/13.6 ± 0.4
= 1.40 ± 0.04
X-rays 19.0 ± 0.2 0 0
Original average Adjusted average
CBE= 0.52 ± 0.02 CBE= 0.36 ± 0.02.
aBy using the data in Table 1, the author has constructed the dose vs RBE relation curve for the neutron beam (Fig. 1), and adjusted the RBE according to the dose. Then,
CBE factors were also adjusted using the adjusted RBE. The values written in italics are the data reported in the original tables in reference [17].
Fig. 1. Dose vs RBE of BMRR neutron beam. The
author constructed the curve using the data in
Table 1. The original data have been reported in the
literature [18].
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Analysis of the relationship between the CBE factor
for BPA to the CNS and the N/B of the 10B level
The values for the CBE factor were plotted as a function of N/B for
the 10B level. The data reported in the literature were applied as the
ratio at each 10B level in the blood [18]. Four data points were
precisely on the straight line, and the CBE factor increased with N/B
of the 10B level (Fig. 3). At 0 for the N/B of 10B level, which doesn’t
exist in actual BPA administration, CBE factors of 0.37 and 0.32 were
predicted for the value before and after adjustment using the cor-
rected RBE, respectively. After adjustment, the CBE factor for BPA to
the CNS late damage is described by the following formula:
CBE factor ¼ 0:32þ N=B × 1:65 ð2Þ
Elucidation of the structure of the CBE factors for BSH
and BPA to the CNS
In BSH–BNCT the vasculature of the normal CNS is irradiated only
from the intraluminal side. Therefore, 0.36 in Fig. 2 can be deﬁned as
an intraluminal CBE (il-CBE) factor for BSH. This value is very close
to 0.32 of the il-CBE factor that BPA has at the virtual condition.
BSH and BPA have very different biological characteristics from each
other, but this indicates they have very similar il-CBE factors.
BPA penetrates normal CNS tissue; thus the vasculature receives
radiation from the extraluminal side. This contribution can be named
the extraluminal CBE (el-CBE) factor. The vascular CBE (v-CBE)
factor consists of the il-CBE and the el-CBE factors. Furthermore, it
is also necessary to consider the contribution of the injury induced in
non-vascular structures. This component of the CBE factor can be
called the non-vascular CBE (nv-CBE) factor. It is obvious that
el- and nv-CBE factors are dictated by the N/B of the 10B level. Thus,
the el-CBE and nv-CBE factors are deﬁned as the products of N/B
and of each element of the el- and nv-CBE factors.
This thought process is described in the following formulas and
Fig. 4:
CBE factor = v-CBE factor + nv-CBE factor ð3Þ
v-CBE factor = il-CBE factor + el-CBE factor ð4Þ
el-CBE factor = N/B × el-CBE factor element ð5Þ
nv-CBE factor = N/B × nv-CBE factor element ð6Þ
Fig. 3. The correlation between the CBE factor for BPA to the
CNS and the N/B of the 10B level before and after the
adjustment of the RBE of the neutron beam.
Fig. 2. CBE factor for BSH to the CNS vs 10B level
in the blood (ppm).
Fig. 4. The dissolution of the CBE factors for BSH and BPA to each component: il-CBE, el-CBE and nv-CBE and their elements.
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CBE factor = il-CBE factor + N/B × el-CBE factor element + N/B
× nv-CBE factor element
¼ 0:32þN=B × ðel-CBE factor elementþnv-CBE factor elementÞ
ð7Þ
The value of (el-CBE factor element + nv-CBE factor element) was
calculated to be 1.65 using Formula 2 and Formula 7.
The structure of the CBE factor and its components
were applied to interpretation of late damage to the skin
and lung
It is thought that injury to a capillary is the cause of dermal necrosis, a
form of the late damage associated with BNCT [12]. This would
mean that the CBE factors for BSH and BPA to the dermal necrosis,
0.86 ± 0.08 and 0.73 ± 0.42 respectively, can be regarded as the
v-CBE factor for each compound, as introduced above. From this, the
quantitative relationship between the il- and el-CBE factors, which
are components of the v-CBE factor, was analyzed using the above
values in a subsequent step.
10B existing in extraluminal tissue delivers a larger radiation dose
to the vasculature than that delivered by intraluminal 10B, even when
the 10B level in the extraluminal tissue is equal to that in the blood
(N/B = 1). The ratio between these two radiation doses obviously
varies depending on the vascular diameter. Furthermore, since the
LETs of an α-particle and a 7Li nucleus change throughout their
extremely short track ranges, this means that these particles cause bio-
logical injury of varying degree to the vasculature depending on the
location of the nuclear reaction. For this geometric and biological
complexity of action, the term ‘geometric biological factor’ (GBF)
was introduced (Fig. 5). The GBF is deﬁned as the ratio of the bio-
logical radiation dose delivered from both sides of the vasculature
wall when the 10B level in the extraluminal tissue is equal to that in
the blood (N/B = 1).
Consequently, the mutual relationship between the il-CBE factor,
el-CBE factor and el-CBE factor element can be written as follows:
el-CBE factor = N/BB × el-CBE factor element
el-CBE factor element = il-CBE factor × GBF
ð8Þ
By using the CBE factors for BSH and BPA to the dermal
necrosis (0.86 ± 0.08 and 0.73 ± 0.42, respectively), GBFs for BSH
and BPA were calculated. N/B of the 10B level for BSH and BPA
reported in the literature were also used for the calculation [12], and
the GBFs for BSH and BPAwere 1.39 and 1.52, respectively.
The GBF for BPA was applied to analysis of CBE factor for late
damage to the lung. Values of 1.1 for the N/B of 10B level and 2.3 for
the CBE factor were reported in the literature concerned [21, 22].
Using these values, 0.32 of il-CBE factor and 1.52 of GBF for BPA,
the elements of el-CBE factor and nv-CBE factor were calculated as
follows using Formulas 3–6 and 8:
CBE factor ð¼ 2:3Þ¼ v-CBE factorþ nv-CBE factor
¼ il-CBE factorþ el-CBE factorþ nv-CBE factor
¼ 0:32þ N=B × ðel-CBE factor elementþ nv-CBE factor elementÞ
¼ 0:32þ 1:1 × ðil-CBE factor × GBF + nv-CBE factor element)
¼ 0:32þ 1:1 × ð0:32 × 1:52þ nv-CBE factor elementÞ
el-CBE factor element = 0:49
nv-CBE factor element = 1:31
nv-CBE factor = 1:44
Consequently;CBEfactor ¼ 0:32þ N=B × 1:80:
DISCUSSION
The data on CBE factors for BSH and BPA for radiation myelopathy
was analyzed and the ﬁgures were compared. As a result of the analysis,
the CBE factor for BSH was found not to be inﬂuenced by the 10B
level in the blood, but was constant (Table 2 and Fig. 2). Morris et al.
noted this characteristic of BSH [17]. By theoretical calculation, Kitao
et al. estimated that the vascular wall received 6–7 Gy during one appli-
cation of BNCT, i.e. one-third to one-ﬁfth of the 10B(n,α)7Li dose
to the blood assuming the wall thickness was 1 μm and the outer diam-
eter of the vasculature was 20 μm [23]. However, when large RBEs
of the particles are considered, the CBE factor is too small compared
with the estimated physical dose to the vascular wall.
The CBE factor for BPA was precisely dictated by the N/B of the
10B level and the value in its virtual state, i.e.10B is existing only in the
blood, and it is close to the CBE factor for BSH after the adjusting
for the corrected RBE of the neutron beam (Fig. 2 vs Fig. 3). From
this analysis, the il-CBE factor, which is derived from the 10B level in
the blood, could be extracted from the CBE factor. In comparison,
the il-CBE factor for BSH was only a little larger than that of BPA in
its virtual state. The 10B level of BSH in the blood plasma is a little
higher than that of BPA, even if their 10B levels in the blood are
equal; this is because BSH is relatively difﬁcult take up into the cells
[24]. The difference between the 10B levels in the plasma (P) is con-
ﬁrmed by the measurement of BNCT patients’ blood samples. The
P/Bs for the 10B level were 1.27 ± 0.12 and 1.57 ± 0.12 for BPA and
BSH, respectively (unpublished data). This means that the vascular
endothelium was exposed to 10B at a higher level in the plasma in the
case of BSH compared with BPA. This difference between the two
boron compounds may be able to explain the difference in the il-CBE
factors for BSH and BPA qualitatively. Though the 10B levels in the
plasma were different, the radiation doses were calculated from the
10B levels in the blood rather than the plasma, and both radiation
Fig. 5. The introduction of GBF to correlate el-CBE factor
with il-CBE factor.
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doses were equal. Consequently, the il-CBE factor for BSH was
higher than that for BPA.
Injury to vasculature is thought to be the cause of dermal necrosis,
a late adverse effect of the skin. This has been fairly well established
by pathological and radiobiological studies on X-ray–irradiated
tissues. The CBE factors for BPA and BSH for dermal necrosis were
very similar; this ﬁnding also supports the idea that injury to the vas-
culature is a primary cause of radiation necrosis of the skin [12].
Using the above idea and the CBE factors reported, the el-CBE factor
and the el-CBE factor element could be extracted from the structure
of the CBE factor. It was necessary to introduce the term ‘GBF’,
which relates the el-CBE factor to the il-CBE factor. The GBFs for
BSH and BPA were also similar (1.39 vs 1.52). These values were
obtained assuming that the dermal necrosis was completely attribut-
able to vascular injury, and that the il-CBE and el-CBE factors were
independent of the kinds of tissues; however, the degree of contribu-
tion of vascular injury to late damage varies with the organs. There-
fore, it is impossible to completely eliminate the possibility of
interfusion of a part of nv-CBE factor into GBF.
In the analysis of late damage to the lung, there was a residue after
subtracting il-CBE and el-CBE from the total CBE factor. It was pos-
sible to explain the CBE factor by including the nv-CBE factor. This
supports the two biological processes established by pathological and
radiobiological studies of late damage of X-rays to the lung [20]. The
nv-CBE factor for BPA was 1.44—very close to the CBE factor (1.4)
assessed no later than 110 days after BNCT [22]. This agreement
seems unlikely to be due to coincidence. Further investigation of this
ﬁnding is necessary. When the same analysis was performed on the
CBE factor for BPA for damage to the CNS, the nv-CBE factor
element was 1.16, which was a little smaller than that for damage to
the lung (=1.31). This difference means that non-vascular injury con-
tributes to late damage to the lung more than it does in late damage
to the CNS.
The CBE factor was able to be divided into vascular and non-
vascular components, and investigation of the precise microdistribu-
tion of 10B in tissues has been possible by a simple and rapid method
[25]. This method also enables estimation of the microdistribution of
10B(n,α)7Li dose in tissues. Therefore, by using these methods, the
CBE factors for some organs may be determined fairly precisely
without animal experiments, especially for organs in which vascular
injury induces the late damage. For example, it is thought that late
radiation damage to the liver presents as veno-occlusive disease
(VOD), characterized by central vein thrombosis whereby occlusion
of the centrilobular veins causes atrophy and loss of the surrounding
hepatocytes [26]. Thus, the primary cause of the late radiation
damage to the liver is vascular injury, so the CBE factor for BPA was
extrapolated from the N/B of the 10B level in the liver after BPA
administration. The values of 1.09 or 1.47 were applied to the calcula-
tion as the N/B of 10B level in the liver [22, 27]. Thus, a CBE factor
of 0.85 or 1.04 could be estimated for the late damage to the liver
without animal experimentation. In the case of BSH, a CBE factor of
1.00 can be obtained using 1.27 as the N/B of the 10B level for calcu-
lation [27]. A pioneering clinical trial of BNCT for patients with mul-
tiple liver metastases was performed by following a procedure
reported from Italy [28]. The liver was totally extracted from the
patient after BPA administration, transported and irradiated with neu-
trons at a research reactor site. Thereafter, the liver was returned to
the patient. Throughout the clinical course, the late adverse effect did
not appear. The CBE factor of ∼1.0 for BPA to the liver predicted in
this paper is smaller than the value for late damage to the brain that is
usually used in clinical BNCT to the malignant glioma, as described
later. When the clinical outcomes of BNCT to liver tumors and brain
tumors are considered together, the CBE factor predicted by the
method in this paper seems reliable.
BNCT for malignant brain tumors has been tried by many
groups. However, there are many values for CBE factors for CNS
damage reported in the literature and researchers often waver in the
choice of an optimum value. In Japan, researchers in KURRI and
their collaborators are irradiating neutrons while continuously infus-
ing with BPA to maintain the 10B level in the blood. The N/B of the
10B level was estimated to be between 0.6 and 0.7, based upon the
data by 18F-BPA PET studies on animals and patients [29, 30]. When
this ratio was applied to the calculation of the CBE factor, it ranged
from 1.31 to 1.48. Therefore, the value in clinical use was conﬁrmed
to be rational [31]. It is well known (from PET examination of
patients) that the T/B and N/B of the 18F-BPA level do not change
concurrently with time after 18F-BPA injection. An accumulation
of 18F-BPA in a tumor reaches a plateau rapidly. However, the level of
18F-BPA gradually increases with time in the normal brain, in spite of
a decline in the 18F-BPA level in the blood [30, 32]. In other words,
CBE factors for a normal brain are changing with time. When a
change of CBE factor with the N/B of the 10B level is considered, the
best timing of neutron irradiation should be selected to give the highest
dose ratio between the tumor and the normal CNS. Thus, the best
timing for neutron irradiation should be incorporated in future sophisti-
cated treatment planning for BNCT. The formula for predicting the
CBE factor may also be useful when seeking to reduce the N/B of the
10B level in order to decrease the effect on the normal brain [33].
CONCLUSION
The structure of the CBE factor was revealed by analyzing experimental
data previously reported in the literature. The results reported here
should be useful in enabling prediction of CBE factors fairly precisely,
without the need for animal experiments for every organ. Thus, basic
and clinical research into BNCT can be expected to accelerate.
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